Nature Communications (Oct 2022)
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
- Filipe Correia Martins,
- Dominique-Laurent Couturier,
- Ines de Santiago,
- Carolin Margarethe Sauer,
- Maria Vias,
- Mihaela Angelova,
- Deborah Sanders,
- Anna Piskorz,
- James Hall,
- Karen Hosking,
- Anumithra Amirthanayagam,
- Sabina Cosulich,
- Larissa Carnevalli,
- Barry Davies,
- Thomas B. K. Watkins,
- Ionut G. Funingana,
- Helen Bolton,
- Krishnayan Haldar,
- John Latimer,
- Peter Baldwin,
- Robin Crawford,
- Matthew Eldridge,
- Bristi Basu,
- Mercedes Jimenez-Linan,
- Andrew W. Mcpherson,
- Nicholas McGranahan,
- Kevin Litchfield,
- Sohrab P. Shah,
- Iain McNeish,
- Carlos Caldas,
- Gerard Evan,
- Charles Swanton,
- James D. Brenton
Affiliations
- Filipe Correia Martins
- Department of Obstetrics and Gynaecology, University of Cambridge
- Dominique-Laurent Couturier
- Cancer Research UK Cambridge Institute, University of Cambridge
- Ines de Santiago
- Cancer Research UK Cambridge Institute, University of Cambridge
- Carolin Margarethe Sauer
- Cancer Research UK Cambridge Institute, University of Cambridge
- Maria Vias
- Cancer Research UK Cambridge Institute, University of Cambridge
- Mihaela Angelova
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Deborah Sanders
- Cancer Research UK Cambridge Institute, University of Cambridge
- Anna Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge
- James Hall
- Cancer Research UK Cambridge Institute, University of Cambridge
- Karen Hosking
- Cambridge University Hospitals
- Anumithra Amirthanayagam
- Department of Gynaecological Oncology, Cambridge University Hospitals
- Sabina Cosulich
- Early Oncology R&D, Astrazeneca
- Larissa Carnevalli
- Early Oncology R&D, Astrazeneca
- Barry Davies
- Early Oncology R&D, Astrazeneca
- Thomas B. K. Watkins
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Ionut G. Funingana
- Cancer Research UK Cambridge Institute, University of Cambridge
- Helen Bolton
- Department of Gynaecological Oncology, Cambridge University Hospitals
- Krishnayan Haldar
- Department of Gynaecological Oncology, Cambridge University Hospitals
- John Latimer
- Department of Gynaecological Oncology, Cambridge University Hospitals
- Peter Baldwin
- Department of Gynaecological Oncology, Cambridge University Hospitals
- Robin Crawford
- Department of Gynaecological Oncology, Cambridge University Hospitals
- Matthew Eldridge
- Cancer Research UK Cambridge Institute, University of Cambridge
- Bristi Basu
- Cambridge University Hospitals
- Mercedes Jimenez-Linan
- Department of Histopathology, Cambridge University Hospitals
- Andrew W. Mcpherson
- Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre
- Nicholas McGranahan
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute
- Kevin Litchfield
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Sohrab P. Shah
- Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre
- Iain McNeish
- Department of Surgery and Cancer, Imperial College of London
- Carlos Caldas
- Cancer Research UK Cambridge Institute, University of Cambridge
- Gerard Evan
- Department of Biochemistry, University of Cambridge
- Charles Swanton
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- James D. Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge
- DOI
- https://doi.org/10.1038/s41467-022-33870-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma. Here we show that identification of clonal somatic copy number alterations in frequently amplified cancer genes could inform therapeutics for precision medicine.
